Eversense
The continuous glucose monitoring system can be used to measure glucose levels in adults with diabetes for up to six months.
The arrangement comes alongside new eight-figure investments into the CGM maker, whose business looked to be in dire straits earlier this year.
The Eversense Bridge program is geared toward patients with high-deductible insurance plans or plans that don't cover the full cost of Eversense CGM, and allows them to purchase the system for $99.
Users of the Eversense CGM will be able to transfer their data to Glooko's online diabetes management platform.
Also: Senseonics' Eversense is cleared for use during an MRI; Warby Parker's AR app update.
Interest in digital health is now sprouting up all over DC, from the president’s announcement of a new AI task force to FDA Commissioner’s shout out to digital health in his budget request.
At long last, Eversense, the implantable continuous glucose monitoring system from Senseonics, has received FDA clearance to be marketed in the United States.
Implantable glucose sensor company Senseonics has launched a remote monitoring app for its users in Europe, the Middle East, and Africa, where its CGM system is distributed by Roche.